A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.07.011
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2020English

P3.cr-10 HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer and Response to Crizotinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

Variable Response to ALK Inhibitors in NSCLC With a Novel MYT1L-ALK Fusion

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

P2.13-07 CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Dramatic Response to Alectinib in a Lung Cancer Patient With a Novel VKORC1L1-ALK Fusion and an Acquired ALK T1151K Mutation

Lung Cancer: Targets and Therapy
Oncology
2018English

ROS1-ADGRG6: A Case Report of a Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

A Novel CAMKMT Exon3-Alk Exon20 Fusion Variant Was Identified in a Primary Pulmonary Mucinous Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy